TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06179069: A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Sponsor: Zai Lab (Shanghai) Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 339 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT06179069 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06179069 Rescue Dossier →